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Abstract
The presenilins form part of a complex of membrane proteins that are involved in the proteolytic cleavage of cell-
surface molecules. This article reviews the history of the discovery of the presenilins, their role in the pathogenesis
of Alzheimer’s disease and in the metabolism of the amyloid-b precursor protein. Unanswered questions about
their biochemical mechanism of action and their effects on Ca
2+ homeostasis are examined.
Alzheimer’s disease (AD) is the most common cause of
dementia in the elderly. Typically 5-10% of the popula-
tion over the age of 65 have dementia, and of these
cases, a large percentage have AD [1]. AD is charac-
terised by the presence of proteinaceous deposits in the
brain [2]. The extracellular amyloid deposits, which are
found in the neuropil (amyloid plaques) and in associa-
tion with small-medium size cerebral blood vessels (cer-
ebral amyloid angiopathy), are composed of a 4 kDa
polypeptide known as the amyloid-b protein (Ab) which
is derived by proteolytic cleavage from a much larger
amyloid-b precursor protein (APP) [3]. Ab displays a
spontaneous ability to aggregate into oligomers and lar-
ger fibrillar structures, and it is generally thought that
the accumulation of oligomeric Ab is chiefly responsible
for the neurodegeneration that occurs in AD [4].
For the generation of Ab, APP is first cleaved on the N-
terminal side of the Ab sequence by the b-site APP cleav-
ing enzyme-1 (BACE1), a transmembrane aspartyl pro-
tease [3]. The resulting 99-amino acid residue C-terminal
fragment (C99) is then cleaved by the g-secretase to yield
Ab and a C-terminal APP intracellular domain (AICD)
fragment (Fig. 1). The function of the AICD fragment is
unclear, although it is thought to have a role in intracel-
lular signalling. For example ,A I C Dm a yb ei n v o l v e di n
the regulation of gene transcription, synaptic plasticity
and cytoskeletal dynamics [5].
The major form of Ab possesses 40 amino-acid resi-
dues (Ab1-40). However, other minor species are also
produced which vary in the C-terminal sequence.
Production of a longer 42-residue species (Ab1-42)i s
thought to be intimately associated with AD pathogen-
esis [6]. Ab1-42 aggregates more readily than Ab1-40, and
increased production of Ab1-42 may seed aggregation of
Ab1-40 or other Ab species [4].
Genetic clues to the pathogenesis of AD
Approximately 5% of all AD cases are autosomal domi-
nant [7]. Soon after the complete APP sequence was
cloned in 1987 [8], it became clear that at least one
familial AD (FAD) locus was located on chromosome
21 [9] and attention turned to the APP gene that had
previously been localised t oar e g i o nw i t h i nc h r o m o -
some 21. The first FAD mutation was identified within
the APP gene [10], and soon after, a number of other
APP mutations were also identified [11-13]. All of the
FAD mutations in the APP gene cluster around the
region encoding the Ab sequence, suggesting that they
have some effect on the aggregation or proteolytic pro-
cessing of APP.
APP mutations on chromosome 21 account for only a
small fraction of the total number of FAD cases. It was
clear that multiple FAD loci existed on other chromo-
somes. The first evidence for an FAD locus on chromo-
some 14 [14] came well before the identification of the
locus on chromosome 21. Then, in 1995, FAD mutations
in two presenilin (PS) genes located on chromosome 14
(presenilin-1, PS1) and chromosome 1 (presenilin-2, PS2)
were reported [15-17]. The PS genes encode proteins
that are homologous to the C. elegans sel-12 gene, which
is known to be involved in Notch signalling [18]. This
observation provided that first clue that PS1 may be
involved in cell-surface receptor signalling. To date, >100
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tions in PS2 [19]. The PS genes encode proteins with 8
or 9 transmembrane domains. The proteins are synthe-
sized as ~50 kDa proteins that are subsequently cleaved
by a presenilinase into a ~30 kDa N-terminal fragment
and a ~20 kDa C-terminal fragment, which remain asso-
ciated with each other [20].
PS mutations are linked to g-secretase activity [21].
Specifically, it has been observed that FAD mutations in
PS1 increase the proportion of C99 that is cleaved by g-
secretase at position 42 of the Ab sequence. The altered
cleavage pattern causes increased production of the
more pathogenic Ab1-42. While the first impression may
be that these are “gain-of-function” mutations, such a
conclusion is difficult to reconcile with the large number
of FAD mutations that have been identified, particularly
in PS1. Instead, mutations in PS are more likely to be
“loss-of-function” mutations [22] in which a decrease in
t h er a t eo fg-secretase cleavage of APP leads to an
increase in the proportion of Ab1-42. PS1 knockout has
been shown to cause an 80% decrease in Ab production
[23], while combined PS1 and PS2 knockout abolishes
g-secretase activity and hence Ab production [24]. In
addition, g-secretase activity co-purifies with a high
molecular weight complex that contains PS1 and several
other proteins (nicastrin, aph-1 and pen-2). It is now
known that the g-secretase consists of a complex of pro-
teins of which PS, nicastrin, aph-1 and pen-2 are the
principal components. Expression of all 4 proteins in
cells is necessary for g-secretase activity [25].
Inhibitor studies demonstrate that the g-secretase is a
member of the aspartyl protease family [26]. All mem-
bers of this family require two aspartyl residues for
enzyme activity [27]. Some aspartyl proteases
(e.g. BACE1) have two aspartyl residues within a single
subunit, but other proteases have only one aspartyl resi-
due, and therefore dimerization is needed to activate the
enzyme. The amino-acid sequence of both PS1 and PS2
contains two conserved aspartyl residues within two
domains predicted to be membrane spanning. These
two aspartyl residues are thought to form part of the
catalytic domain [28]. In support of this idea, mutation
of these two residues has been shown to cause loss of
g-secretase activity [29]. In addition, affinity labelling
experiments demonstrate that g-secretase inhibitors bind
directly to PS [30,31].
While the exact number of g-secretase substrates is
unknown, a large number of transmembrane proteins are
reportedly cleaved by the enzyme [32,33]. Some of the
g-secretase substrates (other than APP) include APLP2,
Notch, Delta, and tumour necrosis factor-a converting
enzyme (TACE). Of these proteins, Notch and Delta may
be the most important as some abnormalities or toxicities
associated with g-secretase inhibition or knockdown
could be due to failure of the Notch/Delta signalling
pathway [34]. Cleavage of Notch by g-secretase produces
Figure 1 Amyloidogenic processing of the b-amyloid precursor protein (APP) by BACE1 and g-secretase. Initially, BACE1 cleaves APP on
the N-terminal end of the Ab sequence to yield a large secreted N-terminal fragment (sAPPb) and a smaller membrane-associated C-terminal
stub (C99), which is then cleaved by the g-secretase complex to yield Ab and an APP intracellular domain (AICD). Secreted Ab aggregates in the
extracellular environment to form neurotoxic oligomers.
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terpart of the AICD produced from APP. Like AICD, the
NICD has an important signalling functions. For exam-
ple, NICD can translocate to the nucleus where it acti-
vates the transcription factor CBF1/JBP-Jkappa,
regulating downstream gene expression [35]. Because
g-secretase inhibition could lead to unwanted side effects
or toxicities, its potential as a therapeutic target for AD is
uncertain. Unless a method can be found to inhibit
g-secretase processing without inhibiting other proteoly-
tic cleavage events, it may be difficult to develop a suc-
cessful AD therapeutic based on g-secretase inhibition,.
However, there may be ways around this problem. For
example, if a successful AD therapy can be achieved by
only partially lowering Ab production, rather than by
abolishing Ab production, then it may possible to use
doses of a g-secretase inhibitor that are low enough to
produce sufficient inhibition of the g-secretase for thera-
peutic purposes, but which avoid some of the unwanted
side effects. Such a strategy could conceivably be
employed in combination with other anti-Ab agents
(e.g. b-secretase inhibitors), if they are available.
Unanswered questions about PS
While there is now clear consensus that PS forms part
of the g-secretase complex, there are still many unan-
swered questions. One question is how the PS family of
proteins evolved. Although there are superficial morpho-
logical similarities between PSs and some other pro-
teases, the PSs and their homologues do not share any
significant amino-acid sequence homology with known
proteases or hydrolases. Presumable, any similarities PS
shares with other aspartyl proteases (e.g. mechanism,
substrate specificity, inhibitor profile etc.) must have
arisen through convergent evolution. The evolutionary
history of the PSs is further complicated by the finding
that a PS homologue is present in plants where it per-
forms functions apparently unrelated to g-secretase
activity [36]. Is it possible that PS has a function unre-
lated to proteolytic cleavage? There is certainly evidence
for this idea (see below).
A second question is how intramembranous proteolysis
of APP occurs. Both the scissile bond in APP and the
active site aspartates in PS are buried deep in the lipid
membrane [28], and it is difficult to understand how
hydrolytic cleavage can occur in such a non-aqueous
environment. Attempts to determine a 3-dimensional
structure for the g-secretase complex using cryo-electron
microscopy have not yet resolved this issue [37,38].
Four major families of proteins which catalyse regu-
lated intramembranous proteolysis (RIP) have been
reported, the presenilin/g-secretase family and the signal
peptide proteases, which are aspartyl proteases, the site
2 proteases (metalloproteases) and the rhomboid
proteases (serine proteases) [39]. The crystal structure
of a rhomboid protease [40] provides some clues as to
how the g-secretase could cleave APP. It is clear that
the active site in the rhomboid proteases is not buried
deep within the lipid bilayer, but is instead formed by a
V-shaped opening that faces laterally on one site of the
lipid membrane and is exposed to the aqueous environ-
ment. The structure of rhomboid proteases suggests
that substrates may extend into the catalytic domain
where they are cleaved. Thus, although the region that
is cleaved may be within the transmembrane domain,
the scissile bond must be outside a lipid environment
for cleavage to occur.
A similar mechanism could occur within the g-secretase/
PS complex (Fig. 2). Indeed, the idea that the transmem-
brane domain of APP must be partially uncoiled in order
to be cleaved is quite attractive, because it could explain
why a-secretase or b-secretase cleavage occurs first, before
g-secretase cleavage. It is tempting to speculate that a-o r
b-secretase cleavage could destabilise the structure of APP
within the membrane, causing the protein to slip in such a
manner that it can enter the active site of the g-secretase
complex (Fig. 2).
The possibility that C99 needs to partially slip out of
the membrane may also explain why g-secretase cleaves
APP at multiple sites. While the commonly held view is
that g-secretase cleavage involves the two main cleavage
sites (positions 40 and 42 of the Ab sequence), the
actual cleavage pattern is much more complex. Several
different cleavage sites close to the C-terminal end of
the Ab sequence have been identified. For example, sev-
eral C-terminally truncated Ab species can be produced,
indicating that other cleavage sites exist [41]. It might
be expected that if the first g-secretase cleavage occurs
at position 40 or 42, that the AICD fragment would
then commence its N-terminus at position 41 or 43.
However, this is not the case. Most studies indicate that
AICD begins at or close to position 49, which is referred
to as the ε cleavage site [42]. In addition to this site, a
ζ-cleavage site has been identified at position 46 [43]. It
is highly likely that the g-secretase cleaves at this ζ-site
as well, as ζ-cleavage is inhibited by g-secretase inhibi-
tors [43]. Cleavage of C99 could occur sequentially with
the total amount of slippage of the C99 peptide dictat-
ing the final cleavage position. Of course, such a possibi-
lity must remain speculative until the idea is tested
experimentally.
Another question is whether PSs have functions that
are entirely unrelated to proteolytic activity. Numerous
studies suggest that PS functions to regulate diverse
activities such as Wnt signalling, neurogenesis, cell
adhesion, synapse formation and apoptosis [44]. It is not
the aim of this review to cover this extremely diverse
group of studies, as it has been well reviewed previously
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tions can be explained by a g-secretase activity. In this
context, it is worth noting that some functions of PS do
appear to be unrelated to g-secretase. For example,
although PS1 interacts with b-catenin, g-secretase activ-
ity is not needed for this interaction as it is not affected
by g-secretase inhibitors [45].
The plot thickens - the role of calcium
Despite the evidence that PS forms the catalytic subunit
of the g-secretase complex, another putative role of PS
has emerged. Recent studies show that mutations in PS
disrupt Ca
2+ homeostasis; however, the cause of this dis-
ruption remains obscure. Dysregulation of intracellular
Ca
2+ levels is thought to be an important mechanism in
AD pathogenesis [46]. Therefore, PS-mediated effects on
Ca
2+ may be important for understanding the pathogen-
esis of AD. However, the question is whether PS muta-
tions cause AD by influencing APP metabolism, Ca
2+
levels, or both. It has been proposed that PS is an ion
channel in the endoplasmic reticulum (ER) and that the
FAD mutations increase ion channel permeability [47].
However, other mechanisms seem likely. Studies have
shown that PS-regulates the release of Ca
2+ via ryano-
dine or inositol 1,4,5-trisphosphate (IP3)c h a n n e l s
[48,49], although, once again, the mechanism is unclear.
PS mutations alter PIP2 metabolism and regulate cation
flux through transient receptor potential M7 channels
[49], and more recently, Cheung et al. [50] have shown
that PS regulates Ca
2+ channel gating via a mechanism
involving the IP3 receptor. PS mutations may also
decrease the activity of the sarco ER Ca
2+ ATPase
(SERCA) pump [51].
However, it is the link between g-secretase cleavage
and intracellular Ca
2+ stores which is the most intri-
guing aspect. Cheung et al. [50] found that PS mutant-
induced enhancement of Ab secretion can be abolished
by IP3 receptor knockout, indicating that g-secretase
activity is controlled downstream of PS by IP3. How this
finding relates to the hypothesis that PS is the catalytic
subunit of the g-secretase needs to be explored further.
Conclusions
While much progress has been made in elucidating the
structure and metabolism of PS, its binding partners and
the relationship between FAD mutations and Ab produc-
tion, many questions remain unanswered. Experiments
involving gene knockout, overexpression and mutagenesis,
and affinity labelling argue strongly that PS is the catalytic
subunit of the g-secretase. However, the role of other com-
ponents of the g-secretase complex (nicastrin, aph1, pen2)
remains uncertain. The mechanism by which g-secretase
cleaves within the transmembrane domain also remains
unclear. Does PS cleave in the hydrophobic environment
of the lipid membrane, or does the substrate of cleavage
(C99 or C83) slip out of the lipid bilayer prior to cleavage?
The latter mechanism seems like a real possibility as it
may explain why a-secretase or b-secretase cleavage of
APP is required before g-secretase cleavage. It is certainly
possible that cleavage at the N-terminus of the Ab
sequence may destabilise the C-terminal peptide, allowing
for some slippage within the membrane.
Figure 2 Hypothetical model showing how g-secretase/PS may cleave C99 to yield Ab. In this model, PS contains 2 catalytic aspartyl
residues (D) that form part of the active site. The two residues are in an aqueous environment formed by a pocket on one side of the
membrane. After cleavage of APP by BACE1, the product, C99, is destabilised and slips into the active site where it is cleaved to form Ab and
the APP intracellular domain (AICD).
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calcium stores needs to be understood. Of particular
significance here are the findings that FAD mutations
influence inositol phosphate signalling and that inositol
phosphate signalling can, in turn, regulate Ab produc-
tion. While it is possible that FAD mutations have mul-
tiple effects which converge on Ab metabolism, until
the precise mechanism by which PS mutations influence
Ab is understood, there will continue to be more ques-
tions than answers.
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